• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Sunday 01/21/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Medical

  • 5:42 PM

    LOS ANGELES, March 10, 2016, CATS, /PRNewswire/ — Catasys, Inc. (OTCQB: CATS), a provider of proprietary data, predictive analytics, and modeling based behavioral health management services for health plans, announced today that it has launched its OnTrak™-H solution inPennsylvania with one of the nation’s leading health plans.  The plan’s eligible commercial and Medicare Advantage members will be covered under OnTrak-H, a 52-week, multi-phase program in which enrolled members receive medical and psychosocial interventions, as well as intensive care coaching. “We are

    Read more
  • Dario Logo
    3:52 PM

    Broadens platform technology’s applications beyond mHealth and into health and non-health related industrial markets   CAESAREA, Israel, March 9, 2016, DRIO /PRNewswire/ — LabStyle Innovations Corp. (NASDAQ: DRIO), developer of the Dario™ Blood Glucose Monitoring System, announced today the U.S. Patent and Trademark Office has issued the Company patent #9257038 titled, “Fluids testing apparatus and methods of use.” The invention addresses mobile, hand held, miniature laboratory systems and testing of fluids including bodily fluids such as blood, urine, saliva, and

    Read more
  • 3:04 PM

    FRAMINGHAM, MA– ARTH, (Marketwired – Mar 9, 2016) – Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of the AC5 Surgical Hemostatic Device™ (“AC5™”), today announces that it has received an internationally recognized ISO quality certification, marking completion of a critical step for Arch in its plans to commercialize AC5. The certification, which was awarded by British Standards Institution Group America, Inc., attests that the Company’s quality management system complies with the requirements of ISO 13485:2003 for the

    Read more
  • 4:52 PM

    ORLANDO, Fla., March 3, 2016, IMUN, /PRNewswire/ — Immune Therapeutics, Inc. (OTC:BB IMUN), a specialty pharmaceutical company involved in the manufacture, commercialization, distribution and marketing of novel, patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system, today announced the appointment of two new members to its Board of Directors: Clifford A. Selsky, Ph.D., MD, and Paul Akin. “Paul Akin and Dr. Selsky ‘s breadth of knowledge and experience will provide invaluable insight to

    Read more
  • 4:14 PM

    Company Also Announced the Submission of Lodonal(TM) Data for Review in Connection with the New Drug Application to NAFDAC for Use as an Immune Booster and Adjunct Treatment for Human Immunodeficiency Virus ORLANDO, FL, IMUN, / ACCESSWIRE / Immune Therapeutics Inc., a U.S. public company (OTCQB: IMUN) today announced that it has completed its 90-day bridging trail of Human Immunodeficiency Virus positive [HIV+] patients and submitted data to The National Agency for Food and Drug Administration and Control, (NAFDAC) in

    Read more
  • 4:06 PM

    Innovus Pharma’s Aggregate Annual Revenues Expected to Triple to Close to $4.0 Million SAN DIEGO, CA–INNV, (Marketwired – Mar 1, 2016) – Innovus Pharmaceuticals, Inc., (“Innovus Pharma” or the “Company) www.innovuspharma.com (OTCQB: INNV) a company focusing on the commercialization of over-the-counter (“OTC”) and consumer products for men’s and women’s health, vitality and respiratory diseases, announced today the closing of the acquisition for substantially all of the assets of Beyond Human, for a cash purchase price of $630,000. In order to

    Read more
Public Wire Banner